Literature DB >> 16186276

Glycemic status and development of kidney disease: the Framingham Heart Study.

Caroline S Fox1, Martin G Larson, Eric P Leip, James B Meigs, Peter W F Wilson, Daniel Levy.   

Abstract

OBJECTIVE: Diabetes is a major risk factor for the development of kidney disease and is the leading cause of end-stage renal disease in the U.S. Whether pre-diabetes is associated with the development of kidney disease is unclear. RESEARCH DESIGN AND METHODS: Subjects free of chronic kidney disease (CKD) were drawn from the Framingham Heart Study offspring cohort (1991-1995), given an oral glucose tolerance test, and followed for an average of 7 years for development of CKD (glomerular filtration rate [GFR] of <59 ml/min per 1.73 m2 in women and <64 ml/min per 1.73 m2 in men). Multivariable logistic regression models, adjusted for cardiovascular disease risk factors including age, sex, hypertension, smoking, BMI, total and HDL cholesterol levels, and prevalent myocardial infarction or congestive heart failure, were used to estimate the odds of patients developing kidney disease among glycemic categories.
RESULTS: Of 2,398 subjects (53% women; mean age 54 years), 63% were normoglycemic, 29% had impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), 3.4% were newly diabetic, and 4.6% had known diabetes. By glycemic category, mean GFR at follow-up was 87, 85, 82, and 78 ml/min per 1.73 m2, respectively. The fully adjusted odds of developing CKD were 0.98 (95% CI 0.67-1.45), 1.71 (95% CI 0.83-3.55), and 1.93 (95% CI 1.06-3.49) among those with IFG or IGT, newly diagnosed diabetes, or known diabetes, respectively, compared with those who were normoglycemic at baseline. Among participants without diabetes, metabolic syndrome was not associated with kidney disease at follow-up (odds ratio 1.46, P = 0.06).
CONCLUSIONS: Cardiovascular disease risk factors explain much of the relationship between prediabetes and the development of chronic kidney disease. Clinical trials are warranted to determine whether vascular risk factor modification can slow the decline of kidney function among those with pre-diabetes.

Entities:  

Mesh:

Year:  2005        PMID: 16186276     DOI: 10.2337/diacare.28.10.2436

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  67 in total

1.  Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentraxin-3 levels: a case-control study.

Authors:  A R Pradeep; Rahul Kathariya; P Arjun Raju; R Sushma Rani; Anuj Sharma; N M Raghavendra
Journal:  Int Urol Nephrol       Date:  2011-06-03       Impact factor: 2.370

2.  Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes.

Authors:  Laura C Plantinga; Deidra C Crews; Josef Coresh; Edgar R Miller; Rajiv Saran; Jerry Yee; Elizabeth Hedgeman; Meda Pavkov; Mark S Eberhardt; Desmond E Williams; Neil R Powe
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-25       Impact factor: 8.237

3.  Impaired Fasting Glucose and Chronic Kidney Disease, Albuminuria, or Worsening Kidney Function: a Secondary Analysis of the SPRINT.

Authors:  Miguel Bigotte Vieira; João Sérgio Neves; Lia Leitão; Rute Baeta Baptista; Rita Magriço; Catarina Viegas Dias; Ana Oliveira; Davide Carvalho; Finnian R Mc Causland
Journal:  J Clin Endocrinol Metab       Date:  2019-05-07       Impact factor: 5.958

4.  Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes?

Authors:  C Sabanayagam; G Liew; E S Tai; A Shankar; S C Lim; T Subramaniam; T Y Wong
Journal:  Diabetologia       Date:  2009-04-22       Impact factor: 10.122

5.  Insulin resistance, microalbuminuria, and chronic kidney disease.

Authors:  Pantelis A Sarafidis; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

Review 6.  Impaired fasting glucose as a treatment target in diabetes management.

Authors:  Rene A Oliveros; Adrienne S Zion; Yelena Rosenberg; Carrie Lynn Selvaraj; Robert Chilton
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

7.  Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.

Authors:  Naveen Rathi; Paul K Whelton; Glenn M Chertow; William C Cushman; Alfred K Cheung; Guo Wei; Robert Boucher; Paul L Kimmel; Adam P Bress; Holly J Kramer; Catreena Al-Marji; Tom Greene; Srinivasan Beddhu
Journal:  Am J Hypertens       Date:  2019-11-15       Impact factor: 2.689

8.  Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Authors:  Louise Profit; Paul Chrisp; Carole Nadin
Journal:  Core Evid       Date:  2008-06

9.  World Congress on the Insulin Resistance Syndrome, 2009: the kidney, the liver, and insulin resistance.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

Review 10.  Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.